Nidia Leon-Sicairos

Prof. Nidia Leon-Sicairos

Shool of Medicine, Autonomous University of Sinaloa
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in International Journal of Medical Microbiology
Verified
Journal Article
Open access
JCJulio C. Carrero
Julio C. Carrero
MRMagda Reyes-López
Magda Reyes-López
JSJesús Serrano-Luna
Jesús Serrano-Luna
MSMineko Shibayama
Mineko Shibayama
JUJuan Unzueta
Juan Unzueta
MAMireya De la Garza Amaya
Mireya De la Garza Amaya
Amoebiasis is a parasitic disease caused by Entamoeba histolytica (E. histolytica), an extracellular enteric protozoan. This infection mainly affects people from developing countries with limited hygiene conditions, where it is endemic. Infective cysts are transmitted by the fecal-oral route, excysting in the terminal ileum and producing invasive trophozoites (amoebae). E. histolytica mainly lives in the large intestine without causing symptoms; however, possibly as a result of so far unknown signals, the amoebae invade the mucosa and epithelium causing intestinal amoebiasis. E. histolytica possesses different mechanisms of pathogenicity for the adherence to the intestinal epithelium and for degrading extracellular matrix proteins, producing tissue lesions that progress to abscesses and a host acute inflammatory response. Much information has been obtained regarding the virulence factors, metabolism, mechanisms of pathogenicity, and the host immune response against this parasite; in addition, alternative treatments to metronidazole are continually emerging. An accesible and low-cost diagnostic method that can distinguish E. histolytica from the most nonpathogenic amoebae and an effective vaccine are necessary for protecting against amoebiasis. However, research about the disease and its prevention has been a challenge due to the relationship between E. histolytica and the host during the distinct stages of the disease is multifaceted. In this review, we analyze the interaction between the parasite, the human host, and the colon microbiota or pathogenic microorganisms, which together give rise to intestinal amoebiasis.

30 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Debmalya BarhDebmalya Barh
Debmalya Barh
NBNeha Barve
Neha Barve
KGKrishnakant Gupta
Krishnakant Gupta
SCSudha Chandra
Sudha Chandra
NJNeha Jain
Neha Jain
VAVasco Azevedo
Vasco Azevedo
Vibrio cholerae is the causal organism of the cholera epidemic, which is mostly prevalent in developing and underdeveloped countries. However, incidences of cholera in developed countries are also alarming. Because of the emergence of new drug-resistant strains, even though several generic drugs and vaccines have been developed over time, Vibrio infections remain a global health problem that appeals for the development of novel drugs and vaccines against the pathogen. Here, applying comparative proteomic and reverse vaccinology approaches to the exoproteome and secretome of the pathogen, we have identified three candidate targets (ompU, uppP and yajC) for most of the pathogenic Vibrio strains. Two targets (uppP and yajC) are novel to Vibrio, and two targets (uppP and ompU) can be used to develop both drugs and vaccines (dual targets) against broad spectrum Vibrio serotypes. Using our novel computational approach, we have identified three peptide vaccine candidates that have high potential to induce both B- and T-cell-mediated immune responses from our identified two dual targets. These two targets were modeled and subjected to virtual screening against natural compounds derived from Piper betel. Seven compounds were identified first time from Piper betel to be highly effective to render the function of these targets to identify them as emerging potential drugs against Vibrio. Our preliminary validation suggests that these identified peptide vaccines and betel compounds are highly effective against Vibrio cholerae. Currently we are exhaustively validating these targets, candidate peptide vaccines, and betel derived lead compounds against a number of Vibrio species.

2 March 2010 in BioMetals
Verified
Journal Article
Closed access
PDF file
HFHéctor Flores-Villaseñor
Héctor Flores-Villaseñor
Adrian Canizalez-RomanAdrian Canizalez-Roman
Adrian Canizalez-Roman
MRMagda Reyes-Lopez
Magda Reyes-Lopez
KNKamram Nazmi
Kamram Nazmi
MGMireya de la Garza
Mireya de la Garza
JBJan G. M. Bolscher
Jan G. M. Bolscher

1 January 2014 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
JVJorge Velazquez-Roman
Jorge Velazquez-Roman
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos
LHLucio de Jesus Hernández-Díaz
Lucio de Jesus Hernández-Díaz
Adrian Canizalez-RomanAdrian Canizalez-Roman
Adrian Canizalez-Roman
Vibrio parahaemolyticus is one of the most important seafood-borne bacterial in recent years and is the leading causal agent of human acute gastroenteritis, primarily following the consumption of raw, undercooked or mishandled marine products. Until 1996, infections caused by V. parahaemolyticus were generally associated with diverse serovars. However, in February 1996, a unique serovar (O3:K6) of V. parahaemolyticus with specific genetic markers (tdh, toxRS/New and/or orf8) appeared abruptly in Kolkata, India. In subsequent years, O3:K6 isolates similar to those isolated in Kolkata have been reported from food borne outbreaks in Southeast Asia, as well as in the Atlantic and Gulf coasts of the United States (U.S). More recently, there have been reports in Europe, Africa and Central and South America. Specifically, in the American continent, some countries have reported cases of gastroenteritis due to the pandemic O3:K6 strain and its serovariants; the pandemic strain was first detected in Peru (1996, >100 cases), subsequently spreading to Chile in 1998 (>16,804 human cases), to the U.S. in 1998 (>700 cases), to Brazil in 2001 (>18 cases) and to Mexico in 2004 (>1200 cases). The arrival of the pandemic clone on the American continent may have resulted in a significant shift on the epidemic dynamics of V. parahaemolyticus. However, although O3:K6 is the predominant serovar of the recognized clinical strains in some countries in the Americas, a decrease in clinical cases caused by O3:K6 and an increase in cases associated with a new serotype (O3:K59, Chile) have been recently reported. The emergence and worldwide dissemination of O3:K6 and other pandemic strains since 1996 have come to represent a threat to public health and should concern health authorities. This review focuses on the presence, distribution and virulence factors of the V. parahaemolyticus O3:K6 pandemic clone and its serovariants in clinical and environmental strains on the American continent.

1 June 2013 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
Adrian Canizalez-RomanAdrian Canizalez-Roman
Adrian Canizalez-Roman
EGEdgar Gonzalez-Nuñez
Edgar Gonzalez-Nuñez
JVJorge E. Vidal
Jorge E. Vidal
HFHéctor Flores-Villaseñor
Héctor Flores-Villaseñor
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos

15 March 2012 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
PDF file
JVJorge Velazquez-Roman
Jorge Velazquez-Roman
Nidia Leon-SicairosNidia Leon-Sicairos
Nidia Leon-Sicairos
HFHéctor Flores-Villaseñor
Héctor Flores-Villaseñor
SVSantiago Villafaña-Rauda
Santiago Villafaña-Rauda
Adrian Canizalez-RomanAdrian Canizalez-Roman
Adrian Canizalez-Roman
In 2004, more than 1,230 cases of gastroenteritis due to pandemic O3:K6 strains of Vibrio parahaemolyticus were reported in southern Sinaloa, a state in Northwestern Mexico. Recurrent sporadic cases arose from 2004 to 2010, spreading from the south to the north. In the present study, Vibrio parahaemolyticus was detected in both environmental samples and clinical cases along the Pacific coast of Sinaloa during 2004 to 2010. An evaluation was made of the serotypes, distribution of virulence genes, and presence of pandemic O3:K6 strains. A total of 144 strains were isolated from environmental samples (from sediment, seawater, and shrimp), and 154 clinical strains were isolated. A total of 10 O serogroups and 30 serovars were identified in the strains. Environmental strains ( n = 144) belonged to 10 O serogroups and 28 serovars, while clinical strains ( n = 154) belonged to 8 O serogroups and 14 serovars. Ten serovars were shared by both environmental and clinical strains. Among 144 environmental isolates, 4.1% (6/144) belonged to the pandemic clone, with 83.3% containing the orf8 gene and with O3:K6 accounting for 67%. On the other hand, pathogenic strains ( tdh and/or trh ) accounted for 52% (75/144) of the environmental isolates. Interestingly, among 154 clinical isolates, 80.5% (124/154) were pandemic strains, with O3:K6 ( tdh , toxRS new , and orf8 ) representing the predominant serovar (99.2%, 123/124). Overall, our results indicate that in spite of a high serodiversity and prevalence of pathogenic Vibrio parahaemolyticus in the environment, the pandemic strain O3:K6 caused >79% of reported cases between 2004 and 2010 in Sinaloa, Mexico.